Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Jul 08, 7:20 AMNovo Nordisk announces a non-exclusive agreement with Vivani Medical to evaluate its long-acting semaglutide implant NPM-139 for chronic weight management.
Index
-
Market Cap
164.14B
Enterprise Value
183.37B
Income
18.95B
Sales
50.91B
Book/sh
7.05
Cash/sh
0.99
Employees
68794
IPO
Apr 30, 1981
P/E
11.47
Forward P/E
14.86
PEG
-
P/S
3.22
P/B
6.94
P/C
49.22
P/FCF
25.59
EV/EBITDA
6.92
EV/Sales
3.60
Quick Ratio
0.56
Current Ratio
0.79
Debt/Eq
0.72
LT Debt/Eq
0.59
Option/Short
Yes / Yes
EPS (ttm)
4.26
EPS next Y
3.29
EPS next Q
0.79
EPS this Y
-9.58%
EPS next Y
-0.00%
EPS next 5Y
-0.79%
EPS past 3/5Y
26.28% 20.36%
Sales past 3/5Y
23.19% 19.21%
EPS Y/Y TTM
26.24%
Sales Y/Y TTM
16.79%
EPS Q/Q
86.54%
Sales Q/Q
37.63%
Insider Own
0.00%
Insider Trans
-
Inst Own
9.78%
Inst Trans
-2.90%
ROA
24.14%
ROE
73.79%
ROIC
38.15%
Gross Margin
81.84%
Oper. Margin
45.45%
Profit Margin
37.23%
SMA20
4.74%
SMA50
8.11%
SMA200
2.64%
Trades
Shs Outstand
3.37B
Shs Float
3.36B
52W High
71.79 -31.92%
52W Low
35.12 39.18%
Volatility
2.01% 2.58%
ATR (14)
1.35
RSI (14)
62.19
Beta
0.77
Rel Volume
0.35
Avg Volume
14.78M
Volume
5,140,475
Perf Week
0.23%
Perf Month
19.16%
Perf Quarter
29.97%
Perf Half Y
-13.12%
Perf YTD
-3.93%
Perf Year
-29.86%
Perf 3Y
-37.72%
Perf 5Y
12.97%
Perf 10Y
79.18%
Prev Close
48.89
Price
48.88
Change
-0.02%
Date Action Analyst Rating Change Price Target Change
Mar-26-26Initiated Wolfe Research Peer Perform
Mar-18-26Initiated Bernstein Underperform
Mar-18-26Initiated Bernstein Outperform $175
Mar-10-26Downgrade TD Cowen Buy → Hold $42
Mar-03-26Upgrade Morgan Stanley Underweight → Equal-Weight $40
Mar-02-26Downgrade Goldman Buy → Neutral $41
Feb-24-26Downgrade Kepler Buy → Hold
Feb-24-26Downgrade JP Morgan Overweight → Neutral
Feb-23-26Downgrade Deutsche Bank Buy → Hold
Feb-12-26Upgrade Jefferies Underperform → Hold
Today 08:16AM
Jul-08-26 10:34AM
08:02AM
07:11AM
Jul-07-26 02:14PM
09:45AM Loading…
09:45AM
07:59AM
Jul-05-26 02:00AM
Jul-03-26 03:10PM
11:53AM
09:53AM
03:55AM
Jun-30-26 02:43PM
Jun-29-26 05:00AM
Jun-26-26 12:47PM
11:26PM Loading…
Jun-25-26 11:26PM
12:14AM
Jun-24-26 11:35AM
05:00AM
Jun-23-26 07:46PM
Jun-22-26 09:34AM
08:47AM
Jun-19-26 02:01PM
01:46PM
08:32AM
08:08AM
07:41AM
04:49AM
Jun-18-26 01:59PM
06:58AM
04:46PM Loading…
Jun-17-26 04:46PM
03:41PM
03:33PM
11:36AM
08:08AM
Jun-16-26 02:52PM
08:37AM
04:49AM
Jun-15-26 01:56PM
Jun-14-26 04:00AM
Jun-12-26 10:37AM
07:55AM
Jun-11-26 02:24PM
12:22PM
11:45AM
Jun-09-26 03:50PM
03:48PM
02:42PM
02:40PM
Jun-08-26 05:32PM
01:26PM
08:30AM
08:22AM
07:01AM
06:42AM
06:16AM
05:44AM
04:58AM
04:44AM
Jun-07-26 07:35PM
Jun-06-26 02:53PM
10:04AM
Jun-05-26 02:31PM
01:19PM
08:53AM
Jun-04-26 01:16PM
10:22AM
12:01AM
Jun-03-26 04:12PM
04:12PM
12:07PM
09:19AM
09:19AM
06:21AM
04:40AM
May-29-26 07:06PM
10:22AM
06:00AM
May-28-26 06:14PM
06:07PM
03:08PM
02:07PM
12:37PM
09:03AM
07:33AM
07:30AM
07:20AM
07:09AM
06:49AM
04:48AM
May-27-26 12:43AM
May-26-26 02:54PM
09:25AM
May-22-26 11:04AM
08:02AM
02:24AM
May-21-26 02:41PM
02:09PM
12:15PM
09:56AM
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.
Executive VPMr. Karsten Munk Knudsen
PresidentMr. Maziar Mike Doustdar B.A.
EVP of R&DDr. Martin Holst Lange
EVP of PeopleMs. Tania Sabroe
Executive VP of Enterprise IT & Quality and Member of Management BoardMs. Thilde Hummel Bogebjerg